Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2018

May 14, 2018

SELL
$3.65 - $7.95 $2.72 Million - $5.91 Million
-743,974 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$2.85 - $3.95 $1.27 Million - $1.75 Million
443,896 Added 147.93%
743,974 $2.6 Million
Q3 2017

Nov 13, 2017

BUY
$2.45 - $3.65 $735,191 - $1.1 Million
300,078
300,078 $1.1 Million

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.